Athira Pharma Inc (NASDAQ:ATHA) has a beta value of 2.83 and has seen 239.22 million shares traded in the last trading session. The company, currently valued at $32.96M, closed the last trade at $0.61 per share which meant it gained $0.18 on the day or 41.53% during that session. The ATHA stock price is -604.92% off its 52-week high price of $4.30 and 32.79% above the 52-week low of $0.41. If we look at the company’s 10-day average daily trading volume, we find that it stood at 25.1 million shares traded. The 3-month trading volume is 946.16K shares.
The consensus among analysts is that Athira Pharma Inc (ATHA) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Athira Pharma Inc (NASDAQ:ATHA) trade information
Sporting 41.53% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ATHA stock price touched $0.61 or saw a rise of 18.33%. Year-to-date, Athira Pharma Inc shares have moved -75.07%, while the 5-day performance has seen it change 29.52%. Over the past 30 days, the shares of Athira Pharma Inc (NASDAQ:ATHA) have changed 42.33%. Short interest in the company has seen 1.56 million shares shorted with days to cover at 2.74.
Wall Street analysts have a consensus price target for the stock at $18, which means that the shares’ value could jump 96.61% from current levels. The projected low price target is $3.0 while the price target rests at a high of $33.0. In that case, then, we find that the current price level is -5309.84% off the targeted high while a plunge would see the stock gain -391.8% from current levels.
Athira Pharma Inc (ATHA) estimates and forecasts
Figures show that Athira Pharma Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -69.09% over the past 6 months, with this year growth rate of 16.83%, compared to 17.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -81.69% over the past 5 years.
ATHA Dividends
Athira Pharma Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Athira Pharma Inc (NASDAQ:ATHA)’s Major holders
Insiders own 1.95% of the company shares, while shares held by institutions stand at 64.34% with a share float percentage of 65.62%. Investors are also buoyed by the number of investors in a company, with Athira Pharma Inc having a total of 82.0 institutions that hold shares in the company. The top two institutional holders are PERCEPTIVE ADVISORS LLC with over 5.4 million shares worth more than $14.32 million. As of 2024-06-30, PERCEPTIVE ADVISORS LLC held 14.099% of shares outstanding.
The other major institutional holder is BAKER BROS. ADVISORS LP, with the holding of over 3.15 million shares as of 2024-06-30. The firm’s total holdings are worth over $8.36 million and represent 8.2298% of shares outstanding.
